1. Home
  2. NRIX vs PNTG Comparison

NRIX vs PNTG Comparison

Compare NRIX & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • PNTG
  • Stock Information
  • Founded
  • NRIX 2009
  • PNTG 2019
  • Country
  • NRIX United States
  • PNTG United States
  • Employees
  • NRIX N/A
  • PNTG N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • PNTG Medical/Nursing Services
  • Sector
  • NRIX Health Care
  • PNTG Health Care
  • Exchange
  • NRIX Nasdaq
  • PNTG Nasdaq
  • Market Cap
  • NRIX 750.4M
  • PNTG 841.6M
  • IPO Year
  • NRIX 2020
  • PNTG N/A
  • Fundamental
  • Price
  • NRIX $12.00
  • PNTG $25.32
  • Analyst Decision
  • NRIX Strong Buy
  • PNTG Buy
  • Analyst Count
  • NRIX 14
  • PNTG 6
  • Target Price
  • NRIX $26.64
  • PNTG $33.67
  • AVG Volume (30 Days)
  • NRIX 1.7M
  • PNTG 276.2K
  • Earning Date
  • NRIX 10-09-2025
  • PNTG 11-05-2025
  • Dividend Yield
  • NRIX N/A
  • PNTG N/A
  • EPS Growth
  • NRIX N/A
  • PNTG 20.56
  • EPS
  • NRIX N/A
  • PNTG 0.77
  • Revenue
  • NRIX $83,687,000.00
  • PNTG $798,923,000.00
  • Revenue This Year
  • NRIX $58.48
  • PNTG $29.63
  • Revenue Next Year
  • NRIX N/A
  • PNTG $14.84
  • P/E Ratio
  • NRIX N/A
  • PNTG $32.72
  • Revenue Growth
  • NRIX 48.32
  • PNTG 30.58
  • 52 Week Low
  • NRIX $8.18
  • PNTG $21.18
  • 52 Week High
  • NRIX $29.56
  • PNTG $34.39
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 66.65
  • PNTG 59.15
  • Support Level
  • NRIX $10.28
  • PNTG $23.28
  • Resistance Level
  • NRIX $11.70
  • PNTG $25.92
  • Average True Range (ATR)
  • NRIX 0.79
  • PNTG 0.63
  • MACD
  • NRIX 0.24
  • PNTG 0.12
  • Stochastic Oscillator
  • NRIX 98.06
  • PNTG 84.09

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

Share on Social Networks: